David M Margolis

Summary

Affiliation: University of North Carolina
Country: USA

Publications

  1. pmc Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells
    Nancy M Archin
    University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    AIDS 22:1131-5. 2008
  2. pmc Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection
    Nancie M Archin
    University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America
    PLoS ONE 5:e9390. 2010
  3. pmc Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy
    N M Archin
    The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
    Nature 487:482-5. 2012
  4. pmc Combined approaches for HIV cure
    David M Margolis
    Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7042, USA
    Curr Opin HIV AIDS 8:230-5. 2013
  5. ncbi request reprint Attacking HIV provirus: therapeutic strategies to disrupt persistent infection
    David M Margolis
    Departments of Medicine, Microbiology and Immunology, and Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7435, USA
    Infect Disord Drug Targets 6:369-76. 2006
  6. pmc Histone deacetylase inhibitors and HIV latency
    David M Margolis
    Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    Curr Opin HIV AIDS 6:25-9. 2011
  7. doi request reprint Mechanisms of HIV latency: an emerging picture of complexity
    David M Margolis
    Departments of Medicine, Microbiology and Immunology, and Epidemiology, University of North Carolina at Chapel Hill, 3302 Michael Hooker Research Center, CB 7435, Chapel Hill, NC, 27599 7435, USA
    Curr HIV/AIDS Rep 7:37-43. 2010
  8. ncbi request reprint Confronting proviral HIV infection
    David M Margolis
    Department of Medicine, 3302 Michael Hooker Research Building, CB 7435, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7435, USA
    Curr HIV/AIDS Rep 4:60-4. 2007
  9. ncbi request reprint The use of beta-D-2,6-diaminopurine dioxolane with or without mycophenolate mofetil in drug-resistant HIV infection
    David M Margolis
    University of North Carolina at Chapel Hill, 3302 Michael Hooker Research Center, Chapel Hill, NC 27599, USA
    AIDS 21:2025-32. 2007
  10. ncbi request reprint Polyamides reveal a role for repression in latency within resting T cells of HIV-infected donors
    Loyda Ylisastigui
    University of Texas Southwestern Medical Center at Dallas, Department of Medicine, Division of Infectious Diseases, Dallas, Texas 75390 9113, USA
    J Infect Dis 190:1429-37. 2004

Detail Information

Publications52

  1. pmc Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells
    Nancy M Archin
    University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    AIDS 22:1131-5. 2008
    ..Valproic acid and intensified antiretroviral therapy may deplete resting CD4+ T-cell HIV infection. We tested the ability of valproic acid to deplete resting CD4+ T-cell infection in patients receiving standard antiretroviral therapy...
  2. pmc Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection
    Nancie M Archin
    University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America
    PLoS ONE 5:e9390. 2010
    ....
  3. pmc Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy
    N M Archin
    The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
    Nature 487:482-5. 2012
    ....
  4. pmc Combined approaches for HIV cure
    David M Margolis
    Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7042, USA
    Curr Opin HIV AIDS 8:230-5. 2013
    ..We highlight some of the recent studies in this effort...
  5. ncbi request reprint Attacking HIV provirus: therapeutic strategies to disrupt persistent infection
    David M Margolis
    Departments of Medicine, Microbiology and Immunology, and Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7435, USA
    Infect Disord Drug Targets 6:369-76. 2006
    ..Attempts to deplete latent HIV using drugs that alter chromatin structure have entered clinical study...
  6. pmc Histone deacetylase inhibitors and HIV latency
    David M Margolis
    Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    Curr Opin HIV AIDS 6:25-9. 2011
    ....
  7. doi request reprint Mechanisms of HIV latency: an emerging picture of complexity
    David M Margolis
    Departments of Medicine, Microbiology and Immunology, and Epidemiology, University of North Carolina at Chapel Hill, 3302 Michael Hooker Research Center, CB 7435, Chapel Hill, NC, 27599 7435, USA
    Curr HIV/AIDS Rep 7:37-43. 2010
    ..Interrupting processes that maintain latency may allow therapeutic attack of this primary form of persistent HIV infection, but a better understanding of relevant mechanisms in vivo is needed...
  8. ncbi request reprint Confronting proviral HIV infection
    David M Margolis
    Department of Medicine, 3302 Michael Hooker Research Building, CB 7435, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7435, USA
    Curr HIV/AIDS Rep 4:60-4. 2007
    ....
  9. ncbi request reprint The use of beta-D-2,6-diaminopurine dioxolane with or without mycophenolate mofetil in drug-resistant HIV infection
    David M Margolis
    University of North Carolina at Chapel Hill, 3302 Michael Hooker Research Center, Chapel Hill, NC 27599, USA
    AIDS 21:2025-32. 2007
    ..We evaluated the safety, tolerability and antiretroviral activity of beta-D-2,6-diaminopurine dioxolane (DAPD; amdoxovir) with or without mycophenolate mofetil (MMF) in HIV-1 infection following extensive antiretroviral therapy (ART)...
  10. ncbi request reprint Polyamides reveal a role for repression in latency within resting T cells of HIV-infected donors
    Loyda Ylisastigui
    University of Texas Southwestern Medical Center at Dallas, Department of Medicine, Division of Infectious Diseases, Dallas, Texas 75390 9113, USA
    J Infect Dis 190:1429-37. 2004
    ..Pyrrole-imidazole polyamides, small molecules that target specific DNA sequences, can access the nucleus of cells and specifically block transcription-factor binding...
  11. pmc A limited group of class I histone deacetylases acts to repress human immunodeficiency virus type 1 expression
    Kara S Keedy
    Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, 3302 Michael Hooker Research Ctr, CB 7435, Chapel Hill, NC 27599 7435, USA
    J Virol 83:4749-56. 2009
    ..Together, these results suggest that HDAC inhibitors specific for a limited number of class I HDACs may offer a targeted approach to the disruption of persistent HIV-1 infection...
  12. ncbi request reprint Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression
    Loyda Ylisastigui
    Department of Medicine, University of Texas Southwestern Medical Center, Dallas, 75390, USA
    AIDS 18:1101-8. 2004
    ..Histone deacetylase (HDAC), a host mediator of gene repression, inhibits HIV gene expression and virus production and may contribute to quiescence of HIV within resting CD4 T cells...
  13. pmc Depletion of latent HIV-1 infection in vivo: a proof-of-concept study
    Ginger Lehrman
    University of Texas Southwestern Medical Center at Dallas, Department of Medicine, Division of Infectious Diseases, 5323 Harry Hines Boulevard, Dallas, TX 753901, USA
    Lancet 366:549-55. 2005
    ..Since the chromatin remodeling enzyme histone deacetylase 1 (HDAC1) maintains latency of integrated HIV, we tested the ability of the HDAC inhibitor valproic acid to deplete persistent, latent infection in resting CD4+ T cells...
  14. ncbi request reprint The regulation of HIV-1 gene expression: the emerging role of chromatin
    Guocheng He
    University of Texas Southwestern Medical Center at Dallas, Department of Medicine, Division of Infectious Diseases, Dallas, Texas 75390 9113, USA
    DNA Cell Biol 21:697-705. 2002
    ..A better understanding of the role of chromatin in the regulation of HIV expression could lead to much-needed therapies against proviral genomes that are being actively transcribed, and those that are quiescent and persistent...
  15. pmc Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors
    Nancie M Archin
    Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 7599 7435, USA
    AIDS 23:1799-806. 2009
    ..Global HDAC inhibition may adversely affect host gene expression, leading to cellular toxicities. Potent inhibitors selective for HDACs that maintain LTR repression could be ideal antilatency therapeutics...
  16. doi request reprint Hexamethylbisacetamide and disruption of human immunodeficiency virus type 1 latency in CD4(+) T cells
    Shailesh K Choudhary
    Departments of Medicine, University of North Carolina at Chapel Hill 27599 7435, USA
    J Infect Dis 197:1162-70. 2008
    ....
  17. pmc Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid
    Nancie M Archin
    University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    AIDS Res Hum Retroviruses 25:207-12. 2009
    ..These results suggest that potent, selective HDAC inhibitors may allow improved targeting of persistent proviral HIV infection, and define parameters for in vivo studies using SAHA...
  18. pmc Suppression of human immunodeficiency virus type 1 (HIV-1) viremia with reverse transcriptase and integrase inhibitors, CD4+ T-cell recovery, and viral rebound upon interruption of therapy in a new model for HIV treatment in the humanized Rag2-/-{gamma}c-
    Shailesh K Choudhary
    Department of Medicine, University of North Carolina, Chapel Hill, 27599, USA
    J Virol 83:8254-8. 2009
    ..Failure of ART in infected mice is associated with the appearance of drug resistance mutations. The hu-Rag2(-/-)gamma(c)(-/-) mouse may therefore facilitate testing of novel approaches to HIV replication and persistence...
  19. pmc c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter
    Guochun Jiang
    Department of Medicine, University of North Carolina at Chapel Hill, 3302 Michael Hooker Research Ctr, Chapel Hill, NC 27599 7435, USA
    J Virol 81:10914-23. 2007
    ..These results expand the understanding of mechanisms that recruit HDAC and maintain the latency of HIV-1, suggesting novel therapeutic approaches against latent proviral HIV infection...
  20. pmc Antiretroviral therapy initiated during acute HIV infection fails to prevent persistent T-cell activation
    Michael J Vinikoor
    Department of Medicine, Center for Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    J Acquir Immune Defic Syndr 62:505-8. 2013
    ..9%, P = 0.008). Shorter time to suppression predicted lower activation at 96 weeks. These results support the hypothesis that very early events in HIV-1 pathogenesis may result in prolonged immune dysfunction...
  21. pmc Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection
    Nancie M Archin
    Department of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA
    Proc Natl Acad Sci U S A 109:9523-8. 2012
    ..These findings reinforce and extend the concept that new approaches will be needed to eradicate HIV infection, and, in particular, highlight the need to target the extremely small but universal, long-lived latent reservoir...
  22. ncbi request reprint The addition of mycophenolate mofetil to antiretroviral therapy including abacavir is associated with depletion of intracellular deoxyguanosine triphosphate and a decrease in plasma HIV-1 RNA
    David M Margolis
    Department of Medicine, Division of Infectious Diseases, North Texas Veterans Health Care Systems, Dallas, USA
    J Acquir Immune Defic Syndr 31:45-9. 2002
    ..The possibility that MMF may enhance the effect of selected NRTIs and be tolerated in late stage HIV disease deserves careful randomized study...
  23. pmc Targeted derepression of the human immunodeficiency virus type 1 long terminal repeat by pyrrole-imidazole polyamides
    Jason J Coull
    Division of Infectious Diseases, Department of Medicine, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390, USA
    J Virol 76:12349-54. 2002
    ..We show that pyrrole-imidazole polyamides targeted to the LTR can specifically block LSF binding both in vitro and within cells via direct access to chromatin, resulting in increased LTR expression...
  24. doi request reprint Pharmaceutical approaches to eradication of persistent HIV infection
    Mary Catherine Bowman
    Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7435, USA
    Expert Rev Mol Med 11:e6. 2009
    ..This review highlights the basic mechanisms for the establishment and maintenance of viral reservoirs and pharmaceutical approaches towards their elimination...
  25. pmc Clonal sequences recovered from plasma from patients with residual HIV-1 viremia and on intensified antiretroviral therapy are identical to replicating viral RNAs recovered from circulating resting CD4+ T cells
    Jeffrey A Anderson
    University of North Carolina at Chapel Hill, 2060 Genetic Medicine Bldg, CB 7042, Chapel Hill, NC 27599 7042, USA
    J Virol 85:5220-3. 2011
    ..Understanding the sources of LLV requires evaluation of all possible reservoirs of persistent HIV infection...
  26. pmc HLA-B*57 elite suppressor and chronic progressor HIV-1 isolates replicate vigorously and cause CD4+ T cell depletion in humanized BLT mice
    Maria Salgado
    Department of Medicine, Center for AIDS Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    J Virol 88:3340-52. 2014
    ..A better understanding of the immunological bases of viral suppression in ES will serve to inform novel approaches to preventive and therapeutic HIV vaccine design...
  27. pmc Counterregulation of chromatin deacetylation and histone deacetylase occupancy at the integrated promoter of human immunodeficiency virus type 1 (HIV-1) by the HIV-1 repressor YY1 and HIV-1 activator Tat
    Guocheng He
    Department of Medicine, Division of Infectious Diseases, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390, USA
    Mol Cell Biol 22:2965-73. 2002
    ....
  28. pmc Latent HIV-1 infection of resting CD4⁺ T cells in the humanized Rag2⁻/⁻ γc⁻/⁻ mouse
    Shailesh K Choudhary
    Department of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA
    J Virol 86:114-20. 2012
    ....
  29. doi request reprint Association of HIV neutralizing antibody with lower viral load after treatment interruption in a prospective trial (A5170)
    Robert J McLinden
    University of Hawai i at Manoa, Honolulu, Hawaii, USA
    AIDS 26:1-9. 2012
    ..We investigated the impact of neutralizing antibodies (NAbs) on CD4 T-cell count and viral load in a cohort of HAART recipients who underwent extended structured treatment interruption...
  30. pmc Therapy for persistent HIV
    Kara S Keedy
    Departments of Medicine, Chapel Hill, North Carolina 27599, USA
    Trends Pharmacol Sci 31:206-11. 2010
    ....
  31. pmc Curing HIV: Pharmacologic approaches to target HIV-1 latency
    Shailesh K Choudhary
    Departments of Medicine, University of North Carolina at Chapel Hill, 27599, USA
    Annu Rev Pharmacol Toxicol 51:397-418. 2011
    ..Finally, we discuss the potential pharmacologic approaches toward targeting viral persistence in different cellular and anatomical reservoirs to achieve a cure of HIV-1 infection...
  32. pmc Emerging strategies to deplete the HIV reservoir
    Nancie M Archin
    Institute for Global Health and Infectious Diseases, and Center for AIDS Research, University of North Carolina at Chapel Hill, School of Medicine, Chapel Hill, North Carolina, USA
    Curr Opin Infect Dis 27:29-35. 2014
    ..This review highlights recent studies undertaken to further advance the search for successful approaches to eradicate HIV infection...
  33. pmc BET bromodomain inhibition as a novel strategy for reactivation of HIV-1
    Camellia Banerjee
    Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA
    J Leukoc Biol 92:1147-54. 2012
    ..Thus, JQ1 may be useful in studies of potentially novel mechanisms for transcriptional control as well as in translational efforts to identify therapeutic molecules to achieve viral eradication...
  34. pmc Generation of HIV latency in humanized BLT mice
    Paul W Denton
    Division of Infectious Diseases, Department of Internal Medicine, Center for AIDS Research, University of North Carolina, Chapel Hill, North Carolina, USA
    J Virol 86:630-4. 2012
    ..These results demonstrate the potential of humanized BLT mice as an attractive model for testing the in vivo efficacy of novel HIV eradication strategies...
  35. pmc Inhibition of HIV fusion with multivalent gold nanoparticles
    Mary Catherine Bowman
    Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7435, USA
    J Am Chem Soc 130:6896-7. 2008
    ..This result suggests that multivalent presentation of small molecules on gold nanoparticle surfaces can convert inactive drugs into potent therapeutics...
  36. pmc Improved measures of quality of life, lipid profile, and lipoatrophy after treatment interruption in HIV-infected patients with immune preservation: results of ACTG 5170
    Daniel J Skiest
    Department of Medicine, Baystate Medical Center, Springfield, MA 01199, USA
    J Acquir Immune Defic Syndr 49:377-83. 2008
    ..Antiretroviral treatment interruption (TI) occurs frequently in routine clinical practice. The consequences of TI on quality of life (QOL), body habitus, and lipid parameters have not been studied...
  37. pmc Targeted cytotoxic therapy kills persisting HIV infected cells during ART
    Paul W Denton
    Division of Infectious Diseases, Department of Medicine, UNC Center for AIDS Research, University of North Carolina School of Medicine, Chapel Hill, North Carolina, United States of America
    PLoS Pathog 10:e1003872. 2014
    ..These results offer proof-of-concept that targeted cytotoxic therapies can be effective components of HIV eradication strategies. ..
  38. pmc Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation
    Sifei Xing
    Department of Medicine, Johns Hopkins University School of Medicine, 720 Rutland Ave, Baltimore, MD 21205, USA
    J Virol 85:6060-4. 2011
    ..The extent to which disulfiram reactivates latent HIV-1 in patient cells is unclear, but the drug alone or in combination may be useful in future eradication strategies...
  39. pmc Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection
    Cynthia L Gay
    University of North Carolina at Chapel Hill, NC 27599, USA
    AIDS 25:941-9. 2011
    ..Characterize responses to non-nucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral treatment (ART) initiated during acute HIV infection (AHI)...
  40. pmc Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection
    Marc C Levesque
    Department of Medicine, Duke University School of Medicine, Durham, North Carolina, United States of America
    PLoS Med 6:e1000107. 2009
    ..While the effect of HIV-1 on depletion of gut CD4(+) T cells in acute HIV-1 infection is well described, we studied blood and tissue B cells soon after infection to determine the effect of early HIV-1 on these cells...
  41. pmc Eradication therapies for HIV Infection: time to begin again
    David M Margolis
    Department of Medicine, Microbiology and Immunology, Epidemiology, Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    AIDS Res Hum Retroviruses 27:347-53. 2011
    ..As then we must now simultaneously develop and optimize platforms and paradigms for the discovery and testing of eradication therapies, and begin to advance candidate therapies toward human testing...
  42. pmc CD4+ T-cell decline after the interruption of antiretroviral therapy in ACTG A5170 is predicted by differential expression of genes in the ras signaling pathway
    Maryanne T Vahey
    Division of Retrovirology, The Walter Reed Army Institute of Research, Rockville, Maryland 20850, USA
    AIDS Res Hum Retroviruses 24:1047-66. 2008
    ..These observations identify specific host cell processes associated with differential outcome in this cohort after TI...
  43. ncbi request reprint Compact quadruple therapy with the lamivudine/zidovudine combination tablet plus abacavir and efavirenz, followed by the lamivudine/zidovudine/abacavir triple nucleoside tablet plus efavirenz in treatment-naïve HIV-infected adults
    Peter J Ruane
    Tower Infectious Diseases Medical Associates, Inc, Los Angeles, California, USA
    HIV Clin Trials 4:231-43. 2003
    ....
  44. ncbi request reprint Interleukin-7 induces HIV type 1 outgrowth from peripheral resting CD4+ T cells
    Ginger Lehrman
    J Acquir Immune Defic Syndr 36:1103-4. 2004
  45. ncbi request reprint Atazanavir for the treatment of human immunodeficiency virus infection
    Anthony J Busti
    Department of Pharmacy Practice, Texas Tech University Health Sciences Center School of Pharmacy, Dallas Ft Worth Regional Campus, Dallas, Texas, USA
    Pharmacotherapy 24:1732-47. 2004
    ..We conclude that atazanavir is a distinctively characteristic protease inhibitor owing to its in vitro potency, once-daily dosing, distinct initial resistance pattern, and infrequent association with metabolic abnormalities...
  46. ncbi request reprint Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression
    Susan Swindells
    Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE 68198 5400, USA
    JAMA 296:806-14. 2006
    ..Maintenance therapy with ritonavir-boosted atazanavir alone is a possible option because of low pill burden, once-daily dosing, safety, and unique resistance profile...
  47. pmc Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy
    C Bradley Hare
    Dept of Medicine, University of California, San Francisco, CA 94110, USA
    Clin Infect Dis 47:421-4. 2008
    ..Mutations remained detectable for at least 48 weeks in some subjects...
  48. ncbi request reprint Cyclosporin A provides no sustained immunologic benefit to persons with chronic HIV-1 infection starting suppressive antiretroviral therapy: results of a randomized, controlled trial of the AIDS Clinical Trials Group A5138
    Michael M Lederman
    Case Western Reserve University, University Hospitals of Cleveland, Cleveland, OH 44106, USA
    J Infect Dis 194:1677-85. 2006
    ..Although the determinants of immune deficiency and immune restoration in chronic human immunodeficiency virus (HIV)-1 infection are not well understood, immune activation has been proposed as being central to the pathogenesis of HIV...
  49. ncbi request reprint Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170
    Daniel J Skiest
    Baystate Medical Center, Springfield, MA 01106, USA
    J Infect Dis 195:1426-36. 2007
    ..We sought to determine the safety of treatment interruption (TI) and to identify parameters that would define patients with human immunodeficiency virus (HIV) for whom TI is safer...
  50. ncbi request reprint Improvement in insulin sensitivity and dyslipidemia in protease inhibitor-treated adult male patients after switch to atazanavir/ritonavir
    Anthony J Busti
    Texas Tech University Health Sciences Center School of Pharmacy, Dallas, Texas, USA
    J Investig Med 56:539-44. 2008
    ..However, its effects on insulin sensitivity have not been elucidated. We conducted this study to test the hypothesis that ATV improves insulin resistance and dyslipidemia...
  51. ncbi request reprint Eliminating persistent HIV infection: getting to the end of the rainbow
    David M Margolis
    J Infect Dis 195:1734-6. 2007
  52. ncbi request reprint Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine, and tenofovir
    Mohammad M Hossain
    Department of Internal Medicine, Division of Infectious Diseases, North Texas Veterans Health Care Systems, Dallas, TX, USA
    Antiviral Res 55:41-52. 2002
    ..These findings provide further rationale for the clinical testing of MMF in combination with ABC, DDI, and TFV...

Research Grants18

  1. Clearing Persistently HIV-Infected CD4+ T Lymphocytes
    David Margolis; Fiscal Year: 2006
    ..Proof-of-concept that depletion of the reservoir of HIV-infected resting CD4+ T cells is achievable could significantly alter the current approach to therapy for HIV infection. ..
  2. Nanocrystal delivery to the CNS to improve HIV therapy
    David M Margolis; Fiscal Year: 2010
    ..We will test novel nanotherapeutics in cell culture and animal model systems of the blood-brain barrier and of HIV infection. ..
  3. Repression of HIV Transcription: from mechanism to anti-latency therapies
    David Margolis; Fiscal Year: 2007
    ..abstract_text> ..
  4. Repression of HIV Transcription-A Pathway to Quiescence
    David Margolis; Fiscal Year: 2003
    ..abstract_text> ..
  5. Repression of HIV Transcription-A Pathway to Quiescence
    David Margolis; Fiscal Year: 2004
    ..abstract_text> ..
  6. Clearing Persistently HIV-Infected CD4+ T Lymphocytes
    David Margolis; Fiscal Year: 2005
    ..Proof-of-concept that depletion of the reservoir of HIV-infected resting CD4+ T cells is achievable could significantly alter the current approach to therapy for HIV infection. ..
  7. Repression of HIV Transcription-A Pathway to Quiescence
    David Margolis; Fiscal Year: 2005
    ..abstract_text> ..
  8. Clearing Persistently HIV-Infected CD4+ T Lymphocytes
    David Margolis; Fiscal Year: 2005
    ..Proof-of-concept that depletion of the reservoir of HIV-infected resting CD4+ T cells is achievable could significantly alter the current approach to therapy for HIV infection. ..
  9. HIV Latency, Epigenetics, and Therapeutics
    David M Margolis; Fiscal Year: 2010
    ..Therefore a more detailed understanding is needed of the epigenetic mechanisms behind persistent infection. ..
  10. Repression of HIV Transcription-A Pathway to Quiescence
    David Margolis; Fiscal Year: 2006
    ..abstract_text> ..
  11. Clearing Persistently HIV-Infected CD4+ T Lymphocytes
    David Margolis; Fiscal Year: 2007
    ..Proof-of-concept that depletion of the reservoir of HIV-infected resting CD4+ T cells is achievable could significantly alter the current approach to therapy for HIV infection. ..
  12. Repression of HIV Transcription-A Pathway to Quiescence
    David Margolis; Fiscal Year: 2002
    ..abstract_text> ..
  13. Nanocrystal delivery to the CNS to improve HIV therapy
    David Margolis; Fiscal Year: 2009
    ..We will test novel nanotherapeutics in cell culture and animal model systems of the blood-brain barrier and of HIV infection. ..